{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-21-000041","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.623556+00:00","generated_at":"2026-06-29T22:25:01.642605+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint","bullets":["Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).","Net loss per share $0.36; adjusted loss per share $0.30; adjusted EBITDA loss $2.7M.","FY2021 revenue guidance raised to $270-275M (growth ~31-33%); adjusted loss per share guidance ~$1.20.","aMAZE trial failed primary efficacy endpoint; safety endpoint met. Potential material adjustments expected in H2 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-21-000041","json":"https://secwatch.observer/filing/0001323885-21-000041.json","markdown":"https://secwatch.observer/filing/0001323885-21-000041.md","text":"https://secwatch.observer/filing/0001323885-21-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388521000041/0001323885-21-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388521000041/atrc-20210804x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:25:01.642605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}